RT Journal Article
SR Electronic
T1 Characteristics and risk factors for SARS-CoV-2 among children in Italy: a cross-sectional study in 20 pediatric centers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.17.21253610
DO 10.1101/2021.03.17.21253610
A1 Lazzerini, Marzia
A1 Sforzi, Idanna
A1 Trapani, Sandra
A1 Biban, Paolo
A1 Silvagni, Davide
A1 Mariani, Ilaria
A1 Villa, Giovanna
A1 Tibaldi, Jessica
A1 Bertacca, Luca
A1 Felici, Enrico
A1 Perricone, Giuseppina
A1 Parrino, Roberta
A1 Gioè, Claudia
A1 Lega, Sara
A1 Conte, Mariasole
A1 Marchetti, Federico
A1 Magista, Annamaria
A1 Berlese, Paola
A1 Martelossi, Stefano
A1 Vaienti, Francesca
A1 Valletta, Enrico
A1 Mauro, Margherita
A1 Dall’Amico, Roberto
A1 Fasoli, Silvia
A1 Gatto, Antonio
A1 Chiaretti, Antonio
A1 Dragovic, Danica
A1 Pascolo, Paola
A1 Pilotto, Chiara
A1 Liguoro, Ilaria
A1 Miorin, Elisabetta
A1 Saretta, Francesca
A1 Trobia, Gianluca
A1 Stefano, Antonella Di
A1 Orlandi, Azzurra
A1 Cardinale, Fabio
A1 Lubrano, Riccardo
A1 Testa, Alessia
A1 Binotti, Marco
A1 Moressa, Valentina
A1 Barbi, Egidio
A1 Armocida, Benedetta
A1 
YR 2021
UL http://medrxiv.org/content/early/2021/03/17/2021.03.17.21253610.abstract
AB Background No study has described factors associated with COVID-19 diagnosis in children.Aim Describe characteristics and risk factors for COVID-19 diagnosis in children tested in 20 pediatric centers across Italy.Methods Cases aged 0-18 years tested for SARS-CoV-2 between February 23 and May 24 2020 were included. Our primary analysis focused on children tested because of COVID-19 suggestive symptoms.Results Among 2494 children tested for SARS-CoV-2, 2148 (86.1%) had symptoms suggestive of COVID-19. Clinical presentation of SARS-CoV-2 included - beside fever (82.4%) and respiratory signs or symptoms (60.4%) – also gastrointestinal (18.2%), neurological (18.9%), cutaneous (3.8%) and other flu-like presentations (17.8%). In multivariate analysis, factors significantly associated with SARS-CoV-2 were: exposure history (adjusted OR 39.83 95%CI 17.52-90.55 p<0.0001), cardiac disease (adjusted OR 3.10 95%CI 1.19-5.02 p<0.0001), fever (adjusted OR 3.05 % 95% CI 1.67-5.58 p=0.0003), and anosmia/ageusia (OR 4.08 95%CI 1.69 −9.84 p=0.002). Among 190 (7.6%) children diagnosed with SARS-CoV-2, only four (2.1%) required respiratory support and two (1.1%) were admitted in ICU, while 100% recovered.Conclusion Recommendations for SARS-CoV-2 testing in children should be updated based on the evidence of broader clinical features. Exposure history, fever, and anosmia/ageusia are strong risk factors for COVID-19 in children, while other symptoms don’t seem helping discriminating in between the SARS-CoV-2 positive and the negative cases. This study confirm that COVID-19 is a mild disease in the general population of children in Italy. Further studies are needed to understand the risk, clinical spectrum and outcomes of COVID-19 in children with specific preexisting conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNon external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy (reference number 01/2020 25.03.2020).Given the purely descriptive and retrospective nature of the study, informed consent was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.